As of August 2023, Galecto has multiple ongoing Phase II clinical programs in fibrosis and cancer, including an orally active LOXL2 inhibitor (GB2064) in a Phase IIa trial for the treatment of myelofibrosis; an orally active galectin-3 inhibitor (GB1211) in a recently completed Phase Ib/IIa trial in liver cirrhosis; and an orally active galectin-3 inhibitor (GB1211) in combination with atezolizumab (Tecentriq) in a separate Phase IIa trial for the treatment of NSCLC.